We disclose a method, comprising administering, to a patient suffering from a cancer, a composition comprising a compound containing a gold atom; and administering, to a portion of the patient's body in which the cancer is present, radiation. We also disclose a kit comprising a composition comprising a compound containing a gold atom; and instructions to perform the method.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof.

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

An energy radiation treatment method comprises: administering a medicinal agent to an affected part; performing energy radiation with a predetermined energy on the affected part; and confirming therapeutic effects by the energy radiation on the affected part, wherein in the administering, a determination based on at least one ultrasound image based on ultrasound waves reflected from the affected part is performed.

Methods for treating a subject with cancer, including administering to the subject an effective amount of an inhibitor of DNAse1L3 and an effective amount of radiation therapy are provided. In some examples, the methods involve enhancing or inducing response of tumor-associated immune cells in the subject, including administering to the subject an effective amount of radiation therapy, and administering to the subject an effective amount of an inhibitor of DNAse1L3, thereby enhancing or inducing the response of tumor-associated immune cells in the subject. In some examples, the tumor-associated immune cells comprise dendritic cells or macrophages.

A boron neutron capture therapy (BNCT) system includes a neutron beam irradiation device, a treatment planning module, and a control module. The neutron beam irradiation device is used to generate a therapeutic neutron beam during irradiation therapy and irradiate same to an irradiated body that has ingested a boron (.sup.10B)-containing drug so as to form an irradiated site. According to medical image data of the irradiated site and a parameter of the therapeutic neutron beam generated by the neutron beam irradiation device, the treatment planning module performs a dosage simulation calculation and generates a treatment plan, the medical image data of the irradiated site comprising tissue-related information and boron (.sup.10B) concentration-related information. The control module retrieves, from the treatment planning module, a treatment plan corresponding to the irradiated body, and controls the neutron beam irradiation device to perform irradiation therapy on the irradiated body according to the treatment plan.

The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.

A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L, L.sup.1, X.sub.1, X.sub.2, X.sub.3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM.sub.2). Also disclosed are the compounds for use in the treatment of diseases modulated AM.sub.2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

##STR00001##